<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33675366</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>29</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>223</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>The Association Between Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Post-COVID-19 Syndrome in Healthcare Workers.</ArticleTitle><Pagination><StartPage>1671</StartPage><EndPage>1676</EndPage><MedlinePgn>1671-1676</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiab120</ELocationID><Abstract><AbstractText>It is currently unknown how post-COVID-19 syndrome (PCS) may affect those infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This longitudinal study includes healthcare staff who tested positive for SARS-CoV-2 between March and April 2020, with follow-up of their antibody titers and symptoms. More than half (21 of 38) had PCS after 7-8 months. There was no statistically significant difference between initial reverse-transcription polymerase chain reaction titers or serial antibody levels between those who did and those who did not develop PCS. This study highlights the relative commonality of PCS in healthcare workers and this should be considered in vaccination scheduling and workforce planning to allow adequate frontline staffing numbers.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pereira</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Wellington Hospital, Circus Road, St John's Wood, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Benjamin H L</ForeName><Initials>BHL</Initials><AffiliationInfo><Affiliation>Computational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Wellington Hospital, Circus Road, St John's Wood, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Giovannantonio</LastName><ForeName>Matteo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Computational Biology and Integrative Genomics, Department of Oncology, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosadas</LastName><ForeName>Carolina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Short</LastName><ForeName>Charlotte-Eve</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Rachael</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureda-Vives</LastName><ForeName>Maci&#xe0;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Natalia</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Day-Weber</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marchesin</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsanovskaja</LastName><ForeName>Ksenia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Eleanor</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Graham P</ForeName><Initials>GP</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tedder</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McClure</LastName><ForeName>Myra O</ForeName><Initials>MO</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Faculty of Medicine, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dani</LastName><ForeName>Melanie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Geriatric Medicine, Hammersmith Hospital, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fertleman</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cutrale Perioperative and Ageing Group, Department of Bioengineering, Imperial College London, London, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MC_PC_19078</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086582" MajorTopicYN="N">Anosmia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006261" MajorTopicYN="N">Headache</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="N">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012140" MajorTopicYN="N">Respiratory Tract Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Healthcare workers</Keyword><Keyword MajorTopicYN="N">Imperial Hybrid DABA</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Post&#x2013;COVID-19 Syndrome</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">multidisciplinary team</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>6</Day><Hour>12</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33675366</ArticleId><ArticleId IdType="pmc">PMC7989400</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiab120</ArticleId><ArticleId IdType="pii">6155862</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>
World Health Organization. Coronavirus disease (COVID-19) global epidemiological situation. 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update---10-november-2020. Accessed 10 November 2020.</Citation></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al. . Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584:430&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Perego E, Callard F, Stras L, Melville-J&#xf3;hannesson B, Pope R, Alwan NA. Why the patient-made term &#x201c;Long Covid&#x201d; is needed. Wellcome Open Res 2020; 5:224.</Citation></Reference><Reference><Citation>
National Institute for Health and Care Excellence. (2020). COVID-19 guideline scope: management of the long-term effects of COVID-19. https://www.nice.org.uk/guidance/ng188. Accessed 18 December 2020.</Citation></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, et al. . Attributes and predictors of long-COVID: analysis of COVID cases and their symptoms 1 collected by the Covid Symptoms Study App. medRxiv [Preprint: not peer reviewed]. 19 December 2020. medRxiv. doi:10.1101/2020.10.19.20214494</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.19.20214494</ArticleId></ArticleIdList></Reference><Reference><Citation>
Greenhalgh T, Ladds E, Knight M, Ravindran D. &#x201c;Long Covid&#x201d;: evidence, recommendations and priority research. 2020; 1 -11. - Written evidence (COV0050). House of Lords Select Committee; 2020 https://committees.parliament.uk/writtenevidence/12345/pdf. Accessed 25 November 2020.</Citation></Reference><Reference><Citation>Seow J, Graham C, Merrick B, et al. . Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol 2020; 5:1598&#x2013;607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7610833</ArticleId><ArticleId IdType="pubmed">33106674</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao XY, Liu W, Li Z-Y, et al. . Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases. medRxiv [Preprint: not peer reviewed]. 21 July 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.07.18.20156810v1.</Citation></Reference><Reference><Citation>Crawford KHD, Dingens AS, Eguia R, et al. . Dynamics of neutralizing antibody titers in the months after severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2021; 223:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7543487</ArticleId><ArticleId IdType="pubmed">33535236</ArticleId></ArticleIdList></Reference><Reference><Citation>Lumley SF, O&#x2019;Donnell D, Stoesser NE, et al. . Antibodies to SARS-CoV-2 are associated with protection against reinfection. medRxiv [Preprint: not peer reviewed]. 19 November 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.11.18.20234369v1.</Citation></Reference><Reference><Citation>Kellam P, Barclay W. The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection. J Gen Virol 2020; 101:791&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7641391</ArticleId><ArticleId IdType="pubmed">32430094</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris BHL, Zuhair M, Di Giovannantonio M, et al. . Asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in a rehabilitation facility: evolution of the presence of nasopharyngeal SARS-CoV-2 and serological antibody responses. J Infect Dis 2021; 223:192&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665566</ArticleId><ArticleId IdType="pubmed">33535238</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention. Real-time RT-PCR primers and probes for COVID-19.2020. https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html. Accessed 4 December 2020.</Citation></Reference><Reference><Citation>Rosadas C, Randell P, Khan M, McClure MO, Tedder RS. Testing for responses to the wrong SARS-CoV-2 antigen? Lancet 2020; 396:e23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7455229</ArticleId><ArticleId IdType="pubmed">32866429</ArticleId></ArticleIdList></Reference><Reference><Citation>Tedder RS, Samuel D, Dicks S, et al. ; Ebola_CP Consortium Investigators . Detection, characterization, and enrollment of donors of Ebola convalescent plasma in Sierra Leone. Transfusion 2018; 58:1289&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5947131</ArticleId><ArticleId IdType="pubmed">29572862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>